was read the article
array:21 [ "pii" => "X2013251409004564" "issn" => "20132514" "doi" => "10.3265/Nefrologia.2009.29.3.5078.en.full" "estado" => "S300" "fechaPublicacion" => "2009-06-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2009;29:203-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3748 "formatos" => array:3 [ "EPUB" => 224 "HTML" => 3009 "PDF" => 515 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699509004567" "issn" => "02116995" "doi" => "10.3265/Nefrologia.2009.29.3.5078.en.full" "estado" => "S300" "fechaPublicacion" => "2009-06-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2009;29:203-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 10013 "formatos" => array:3 [ "EPUB" => 231 "HTML" => 9115 "PDF" => 667 ] ] "es" => array:11 [ "idiomaDefecto" => true "titulo" => "Propiedades cardiometabólicas del Manidipino: ¿Más allá de la reducción de la presión arterial?" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "203" "paginaFinal" => "207" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Cardio-metabolic properties of manidipine: beyond lowering arterial pressure?" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Nisa Buset Ríos, Francisco Rodríguez Esparragón, José Carlos Rodríguez Pérez" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Nisa" "apellidos" => "Buset Ríos" ] 1 => array:2 [ "nombre" => "Francisco" "apellidos" => "Rodríguez Esparragón" ] 2 => array:2 [ "nombre" => "José Carlos" "apellidos" => "Rodríguez Pérez" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X2013251409004564" "doi" => "10.3265/Nefrologia.2009.29.3.5078.en.full" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409004564?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509004567?idApp=UINPBA000064" "url" => "/02116995/0000002900000003/v0_201502091409/X0211699509004567/v0_201502091409/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X2013251409004638" "issn" => "20132514" "doi" => "10.3265/Nefrologia.2009.29.3.5152.en.full" "estado" => "S300" "fechaPublicacion" => "2009-06-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2009;29:208-13" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5011 "formatos" => array:3 [ "EPUB" => 255 "HTML" => 4138 "PDF" => 618 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "Fibrate-induced deterioration of renal function" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "208" "paginaFinal" => "213" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Deterioro de Función Renal Inducido por Fibratos" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig1" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "17218078_f1_p209.jpg" "Alto" => 252 "Ancho" => 397 "Tamanyo" => 21230 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Natalia Polanco, E. Hernández, E. González, E. Gutiérrez Martínez, I. Bello, V. Gutiérrez-Millet, F. García, E. Morales, M. Praga" "autores" => array:9 [ 0 => array:2 [ "nombre" => "Natalia" "apellidos" => "Polanco" ] 1 => array:2 [ "Iniciales" => "E." "apellidos" => "Hernández" ] 2 => array:2 [ "Iniciales" => "E." "apellidos" => "González" ] 3 => array:2 [ "Iniciales" => "E." "apellidos" => "Gutiérrez Martínez" ] 4 => array:2 [ "Iniciales" => "I." "apellidos" => "Bello" ] 5 => array:2 [ "Iniciales" => "V." "apellidos" => "Gutiérrez-Millet" ] 6 => array:2 [ "Iniciales" => "F." "apellidos" => "García" ] 7 => array:2 [ "Iniciales" => "E." "apellidos" => "Morales" ] 8 => array:2 [ "Iniciales" => "M." "apellidos" => "Praga" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699509004630" "doi" => "10.3265/Nefrologia.2009.29.3.5152.en.full" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509004630?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409004638?idApp=UINPBA000064" "url" => "/20132514/0000002900000003/v0_201502091629/X2013251409004638/v0_201502091629/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "X2013251409004556" "issn" => "20132514" "doi" => "10.3265/Nefrologia.2009.29.3.5290.en.full" "estado" => "S300" "fechaPublicacion" => "2009-06-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2009;29:196-202" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4383 "formatos" => array:3 [ "EPUB" => 236 "HTML" => 3648 "PDF" => 499 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "FGF23 in chronic kidney disease and kidney post-transplant patients" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "196" "paginaFinal" => "202" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "El FGF23 en la insuficiencia renal crónica y el post-transplante renal" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig1" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "17018078_f1_p198.jpg" "Alto" => 337 "Ancho" => 398 "Tamanyo" => 16798 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Armando Luis Negri" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Armando Luis" "apellidos" => "Negri" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699509004559" "doi" => "10.3265/Nefrologia.2009.29.3.5290.en.full" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509004559?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409004556?idApp=UINPBA000064" "url" => "/20132514/0000002900000003/v0_201502091629/X2013251409004556/v0_201502091629/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "titulo" => "Cardio-metabolic properties of manidipine: beyond lowering arterial pressure?" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "203" "paginaFinal" => "207" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Nisa Buset Ríos, Francisco Rodríguez Esparragón, José Carlos Rodríguez Pérez" "autores" => array:3 [ 0 => array:3 [ "nombre" => "Nisa" "apellidos" => "Buset Ríos" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 1 => array:3 [ "nombre" => "Francisco" "apellidos" => "Rodríguez Esparragón" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 2 => array:4 [ "nombre" => "José Carlos" "apellidos" => "Rodríguez Pérez" "email" => array:1 [ 0 => "jrodperd@gobiernodecanarias.org" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Unidad de Investigación, Hospital Universitario de Gran Canaria Dr. Negrín Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, España, " "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:3 [ "entidad" => "Unidad de Investigación, Servicio de Nefrología, Hospital Universitario de Gran Canaria Dr. Negrín, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, España, " "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Propiedades cardiometabólicas del Manidipino: ¿Más allá de la reducción de la presión arterial?" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig1" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "17118078_f1_p205.jpg" "Alto" => 434 "Ancho" => 824 "Tamanyo" => 24773 ] ] ] ] "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara">Hypertension and insulin resistance are the most important risk factors for cardiovascular damage.<span class="elsevierStyleSup">1,2</span> Antihypertensive treatment commonly includes the combination of calcium channel antagonists (CA) with angiotensin converting enzyme inhibitors (ACE inhibitors) or angiotensin II receptor blockers (ARBs),<span class="elsevierStyleSup">3</span> since single-agent treatment is not able to reduce blood pressure in most cases.</p><p class="elsevierStylePara">Some studies<span class="elsevierStyleSup">4,5</span> show that anti-hypertensive treatments that include calcium antagonists improve insulin sensitivity. In a study of 158 hypertensive patients with type-2 diabetes, the combination of manidipine and delapril showed results similar to those of olmesartan and hydrochlorothiazide as far as reducing arterial pressure, but with fewer changes in orthostatic arterial pressure, as well as fewer adverse metabolic effects. These data are more interesting for this group of patients, which is especially prone to orthostatic hypotension associated with an increase in morbidity and mortality.<span class="elsevierStyleSup">5</span></p><p class="elsevierStylePara">Preliminary studies of diabetic patients with uncontrolled hypertension and microalbuminuria suggest that, despite adequate treatment with ACE inhibitors or ARBs, manidipine may be given in combination with the renin-angiotensin inhibitors to normalise blood pressure and urinary excretion of albumin in diabetic patients.<span class="elsevierStyleSup">6</span></p><p class="elsevierStylePara">Calcium antagonists constitute a highly heterogeneous class of molecules that may be grouped into phenylalkylamine derivatives, such as verapamil, benzothiazepine derivatives whose prototype is diltiazem, and 1,4-dihydropyridine compounds that include manidipine.<span class="elsevierStyleSup">7</span></p><p class="elsevierStylePara">The first generation of dihydropyridine calcium channel blockers, such as nifedipine, are characterised by their instant release, their short half-life and their rapid absorption. Despite having a favourable metabolic profile, they present some adverse effects, such as sudden drops in arterial pressure, tachycardia and sympathetic activation. In the second generation, that includes amongst others, felodipine and isradipine is characterised by a slower molecular release.<span class="elsevierStyleSup">8</span></p><p class="elsevierStylePara">The latest generation of calcium antagonists, with a long half-life and extended duration of action has shown a clear decrease in arterial pressure and a significant reduction in side effects. On this subject, a trial with 30 obese hypertensive patients treated with amlodipine, manidipine and cilnidipine revealed that these long-acting calcium antagonists reduce arterial pressure, and in addition, reduce insulin resistance, suggesting important cardio-metabolic properties.<span class="elsevierStyleSup">4</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">VOLTAGE-DEPENDENT CALCIUM CHANNELS</span></p><p class="elsevierStylePara">Voltage-dependent calcium channels are classified according to their pharmacological and electrophysiological properties as L, P/Q, N, R and T-type.<span class="elsevierStyleSup">9</span> They are composed of multiple heteromeric subunits: α, β, γ δ. The α1 subunit seems to be responsible for the prinicipal characteristics of these channels.<span class="elsevierStyleSup">10-12</span></p><p class="elsevierStylePara">Unlike the first calcium antagonists that only blocked L-type channels, third-generation blockers, such as manidipine, lercadipine, amlodipine, nivaldipine or efonidipine, are capable of blocking both L-type and T-type channels, the latter are only active during cellular proliferation.</p><p class="elsevierStylePara">L-type channels are activated by intense depolarisations, resulting in a prolonged calcium influx in a large variety of cell types. In this way, they play a central role in the contraction of cardiac and smooth muscle cells (Cav1.2[α<span class="elsevierStyleInf">1C</span>]), are responsible for arterial smooth muscle tone, and have become pharmacological targets in the treatment of hypertension and angina. In the kidney, (Cav1.2[α<span class="elsevierStyleInf">1C</span>] and Cav1.3[α<span class="elsevierStyleInf">1D</span>]) they promote the dilatation of pre-glomerular or afferent arterioles, increasing glomerular hypertension by a considerably. Furthermore, we find other L-type channels in skeletal muscle Cav1.1(α<span class="elsevierStyleInf">1S</span>), brain and kidney (Cav1.2[α<span class="elsevierStyleInf">1C</span>], Cav1.3[α<span class="elsevierStyleInf">1D</span>]), pancreas (Cav1.3[α<span class="elsevierStyleInf">1D]</span>) and retina (Cav1.4[α<span class="elsevierStyleInf">1F</span>]).<span class="elsevierStyleSup">9</span></p><p class="elsevierStylePara">T-channels are expressed in the nervous system (Cav3.1[α<span class="elsevierStyleInf">1G</span>]), brain (Cav3.1[α<span class="elsevierStyleInf">1G</span>], Cav3.2[α<span class="elsevierStyleInf">1H</span>] and Cav3.3[α<span class="elsevierStyleInf">1D</span>]), heart (Cav3.2[α<span class="elsevierStyleInf">1H</span>]), kidney (Cav3.1[α<span class="elsevierStyleInf">1G</span>], Cav3.2[α<span class="elsevierStyleInf">1H</span>]) and liver (Cav3.2[α<span class="elsevierStyleInf">1H</span>]).<span class="elsevierStyleSup">9</span> Their influence in hormone secretion such as renin, aldosterone, atrial natriuretic peptide and insulin has been suggested in multiple occasions. T-type channels are activated by short depolarisations, which provoke a transitory flow of calcium. In post-glomerular or efferent arterioles, only T-type channels and no L-type channels are expressed and this implies that their tone must be controlled by T channels and AT1 angiotensin II receptors. Manidipine and lercanidipine block T-type channels in efferent arterioles, thus diminishing the intraglomerular pressure and also the excretion of albumin; at the same time, they block L-type channels, favouring afferent arteriole dilation. In this way, T-type channel antagonists influence renal haemodynamics through their anti-hypertensive action.<span class="elsevierStyleSup">9,13-15</span> We can therefore consider their effect to be protective against renal damage, since the kidney is one of the targets for end-organ damage in hypertensive and diabetic patients.</p><p class="elsevierStylePara">Non-haemodynamic action of T-type channel antagonists may have multiple beneficial effects by inhibiting inflammatory processes (inhibition of Rho kinase, NF-kB, leukocyte adhesion) and blocking the renin-angiotensin system and the sympathetic nervous system.<span class="elsevierStyleSup">13</span></p><p class="elsevierStylePara">Apart from L and T-type channels, P/Q type channels are found in the brain, kidneys and pituitary gland ([Cav2.1(α<span class="elsevierStyleInf">1A</span>)], N-type channels are found in the brain and nervous system (Cav2.2[α<span class="elsevierStyleInf">1B</span>]) and R-type channels in the brain, heart and pituitary gland (Cav2.3[α<span class="elsevierStyleInf">1E</span>]).<span class="elsevierStyleSup">9</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">MANIDIPINE, ADIPOGENESIS AND INSULIN SENSITIVITY</span></p><p class="elsevierStylePara">The lipotoxicity hypothesis suggests that in type-2 diabetes the adipose tissue looses the ability to accommodate an excess of calories. The loss of adipocyte differentiation causes the excess of calories to accumulate, mainly in the liver, pancreas and muscle tissue, which contributes to the development of insulin resistance.<span class="elsevierStyleSup">16</span> Small adipocytes are sensitive to insulin, unlike the mature ones, which become hypertrophied and insulin-resistant.Therefore, favouring adipogenesis will contribute to lowering insulin resistance in type-2 diabetics.</p><p class="elsevierStylePara">The improvement of insulin sensitivity gained with dihydropyridine calcium antagonists is almost imperceptible.</p><p class="elsevierStylePara">Nifedipine, only blocks L-type channels, worsens insulin resistance and inhibits the release of glucose.<span class="elsevierStyleSup">4</span> However, studies with manidipine show surprising results in this respect. It has already been shown in a randomised clinical trial of 64 hypertensive patients with metabolic syndrome, evaluated according to NCEP/ATPIII criteria, treated with manidipine or amlodipine during 12 weeks that although similar decreases in arterial pressure were observed with both treatments, only the patients treated with manidipine show a significant reduction in insulin resistance.<span class="elsevierStyleSup">17</span> Similarly, the most recent analysis of the effects of the combination of delapril/manidipine compared with olmesartan/hydrochlorothiazide on insulin sensitivity and plasma fibrinogen in obese hypertensive patients showed that the first combination significantly reduced insulin resistance and plasma fibrinogen levels, despite the fact that the decrease in arterial pressure values was similar for both combinations.<span class="elsevierStyleSup">18</span></p><p class="elsevierStylePara">Studies by others have shown that manidipine, but not amlodipine or lercadipine, activates the peroxisome proliferator-activated receptor (PPARγ) in 3T3-L1 adipocytes in the rat.<span class="elsevierStyleSup">19,20</span> In our studies of NIH-3T3 cells treated with manidipine, we observed an increase in the expression of both PPARγ and the adipocyte differentiation 2 (aP2) gene. The latter is an indicator of adipogenesis and possibly expressed after induction of the former (figure 1). These results suggest that manidipine increases insulin sensitivity in hypertensive diabetic patients by stimulating the formation of new adipocytes (unpublished observations). In addition it has been observed that the increase in intracellular calcium inhibits pre-adipocyte differentiation.<span class="elsevierStyleSup">21</span> This is distinct from the well known role of calcium in more rapid processes, such as neurosecretion, excitation or contraction.</p><p class="elsevierStylePara">Adipogenesis, like other differentiation processes, depends on transcription factor promoters such as PPARγ and transcription factor inhibitors, such as the GATA family, which in turn are activated by extracellular signals. Calcium homeostasis was studied with particular attention to the calreticulin, the principal protein that binds to calcium in the lumen of the endoplasmic reticulum, and which is largely responsible for rapid calcium exchange. A study of stem cells and 3T3-L1 pre-adipocytes shows that calreticulin could modulate adipogenesis by means of a negative feedback mechanism. PPARγ is a potent calreticulin transcription activator, since it binds to its promoter. In this way, it increases calreticulin expression, but once calreticulin is over-expressed, it inhibits cis binding of the PPARγ-RxR heterodimer to PPARγ response elements (PPRE), cancelling transcriptional activation of PPARγ by fatty acids. By this mechanism, calreticulin negatively regulates both the expression of PPARγ and other critical pro-adipogenic transcription factors such as C/EBPα.<span class="elsevierStyleSup">22</span></p><p class="elsevierStylePara">The action of manidipine as a calcium channel blocker may prevent calcium from entering the cell thus, decreasing the concentration of calcium in the endoplasmic reticulum and therefore, the concentration of calreticulin, favouring adipocyte differentiation.</p><p class="elsevierStylePara"><span class="elsevierStyleBold">MANIDIPINE: ANTI-INFLAMMATORY, VASOPROTECTIVE AND ANTIOXIDANT EFFECTS</span></p><p class="elsevierStylePara">Oxidative stress plays a fundamental role in the development of atherosclerosis. Several studies demonstrate the beneficial effect of dihydropiridine calcium antagonists on atherosclerotic lesions.<span class="elsevierStyleSup">23</span> The beneficial effects of calcium blockers in macrovascular endothelial cells should be demonstrated and proved using mechanisms that do not include calcium channels, since these are not expressed in endothelial cells.<span class="elsevierStyleSup">24</span> For this reason, some authors have speculated that the action of dihydropyridines on this tissue was related with their lipophilic nature.<span class="elsevierStyleSup">25</span> Toba et al. point out the antioxidant, anti-inflammatory effect of manidipine and other third-generation calcium antagonists such as amlodipine, measured by the increase of expression of endothelial nitrous oxide synthase (eNOS) and the inhibition of the expression of angiotensin converter enzyme (ACE) , but not by its possible action of lowering arterial pressure . In this study, we observe that manidipine normalises the decrease in both the eNOS gene and its protein, and attenuates the over-expression of NAPDH oxidase, VCAM and MCP-1 in the aorta of hypertensive rats.<span class="elsevierStyleSup">26</span></p><p class="elsevierStylePara">Furthermore, manidipine shows another beneficial effect on atherogenesis, since it inhibits the expression of LOX-1, a low-density lipoprotein receptor induced by angiotensin II.<span class="elsevierStyleSup">27</span></p><p class="elsevierStylePara">Sun X et al<span class="elsevierStyleSup">28</span> recently showed that in differentiated mature adipocytes, 3T3-L1 or co-cultures with both cell types, calcitriol increases expression of inflammatory molecules such as MCP-1, MIF, M-CSF, MIP, IL-6, TNF or CD14. Treatment with nifedipine or dinitrophenol inhibits the action of the calcitriol, which reveals a mechanism that is dependent on calcium and mitochondrial uncoupling. Therefore, it would seem that blocking calcium channels with manidipine would produce an antioxidant, antiinflammatory effect by lowering the intracellular calcium level.</p><p class="elsevierStylePara"><span class="elsevierStyleBold">KEY CONCEPTS</span></p><p class="elsevierStylePara">1. Voltage-dependent calcium channels are classified according to their pharmacological and electrophysiological properties as L, P/Q, N, R and T-type. They are composed of multiple heteromeric subunits: α, β, γ and δ. The α1 subunit seems to be responsible for principal characteristic of these channels.</p><p class="elsevierStylePara">2. L-type channels are activated by intense depolarisations that are responsible for the tone of smooth arterial muscle. Ttype channels are activated by short depolarisations, which provoke a transitory flow of calcium.</p><p class="elsevierStylePara">3. Although the improvement in insulin sensitivity achieved with dihydropyridine calcium antagonists is almost imperceptible, we have observed an increase in the relative expression of PPARγ (peroxisome proliferator-activated receptor) and the relative expression of the adipocyte differentiation 2 (aP2) gene. These preliminary results may suggest that manidipine increases insulin sensitivity in hypertensive diabetic patients by stimulating the formation of new adipocytes and preserving PPARγ activity.</p><p class="elsevierStylePara"><a href="grande/17118078_f1_p205.jpg" class="elsevierStyleCrossRefs"><img src="17118078_f1_p205.jpg"></img></a></p><p class="elsevierStylePara">Figure 1. </p>" "pdfFichero" => "P-E-S-A171-EN.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:3 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec440023" "palabras" => array:1 [ 0 => "Resistencia a la insulina" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec440025" "palabras" => array:1 [ 0 => "Manidipino" ] ] 2 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec440027" "palabras" => array:1 [ 0 => "Calcioantagonistas" ] ] ] "en" => array:3 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec440024" "palabras" => array:1 [ 0 => "Insulin resistance" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec440026" "palabras" => array:1 [ 0 => "Manidipine" ] ] 2 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec440028" "palabras" => array:1 [ 0 => "Calcium antagonists" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "<p class="elsevierStylePara">Desde su introducción en la década de los 70, la evolución de los calcioantagonistas ha permitido solventar la incertidumbre inicialmente generada por aquellos fármacos de primera generación. Éstos se caracterizan por una menor disponibilidad oral, una acción vasodilatadora rápida y corta acción. El manidipino surge como un derivado dihidropiridínico de tercera generación con ventajas adicionales reales frente a las generaciones anteriores, como son su alta lipofilicidad, su acción más prolongada y una vida media prolongada a nivel del receptor y, además, algunas ventajas teóricas entre otras, mejoras sobre la función renal reduciendo la presión intraglomerular y la microalbuminuria. Sin embargo, la evaluación clínica de estas últimas propiedades depende aún de los resultados que se deriven de la experiencia clínica. Además de ahondar en su papel en la reducción de la presión arterial, presentamos una breve revisión sobre nuevos aspectos cardiometabólicos de los calcioantagonistas dihidropiridínicos, centrándonos en el manidipino.</p>" ] "en" => array:1 [ "resumen" => "<p class="elsevierStylePara">From its introduction in the decade of the 70’s the evolution of the calcium channel blockers has allowed to resolve the uncertainty initially generated by those first generation drugs. These, are characterized by a smaller oral availability, a fast vasodilator action and a short duration of action. Manidipine arises as a dihydropyridine calcium antagonist of third generation with real additional advantages regarding to previous generations. They show high lipophilia, a more prolonged action and as well as a prolonged average life at the level of his receptor and, in addition, some theoretical advantages among others calcium antagonists, improvements on the renal function by reducing the intraglomerular pressure and microalbuminuria. Nevertheless, the clinical evaluation of these last properties still depends on the results derived from clinical trials. Besides to go deep in its role in their antihypertensive effect, we presented a brief review on new cardiometabolic aspects of these dihydropyridines calcium antagonists focusing in manidipine.</p>" ] ] "multimedia" => array:1 [ 0 => array:7 [ "identificador" => "fig1" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "17118078_f1_p205.jpg" "Alto" => 434 "Ancho" => 824 "Tamanyo" => 24773 ] ] ] ] "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:28 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Mathew B, Francis L, Kayalar A, Cone J. Obesity: effects on cardiovascular disease and its diagnosis. J.Am.Board Fam.Med. 2008; 21: 562-568 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18988724" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Yoshinaga M, Sameshima K, Tanaka Y et al. Association between the number of cardiovascular risk factors and each risk factor level in elementary school children. Circ.J. 2008; 72: 1594-1597 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18756035" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Ueshiba H, Miyachi Y. Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. Intern.Med. 2004; 43: 561-565 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15335180" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Fogari R, Derosa G, Zoppi A et al. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus. Hypertens.Res. 2008; 31: 43-50 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18360017" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005; 65 Suppl 2: 29-39 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16398060" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N.Engl.J.Med. 1999; 341: 1447-1457" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Gojanovic B, Feihl F, Liaudet L, Waeber B. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. J.Renin.Angiotensin.Aldosterone.Syst. 2008; 9: 1-9 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18404602" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hayashi K, Wakino S, Sugano N et al. Ca2+ channel subtypes and pharmacology in the kidney. Circ.Res. 2007; 100: 342-353 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17307972" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Tiwari S, Zhang Y, Heller J, Abernethy DR, Soldatov NM. Atherosclerosis-related molecular alteration of the human CaV1.2 calcium channel alpha1C subunit. Proc.Natl.Acad.Sci.U.S.A 2006; 103: 17024-17029 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17071743" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Abernethy DR, Soldatov NM. Structure-functional diversity of human L-type Ca2+ channel: perspectives for new pharmacological targets. J.Pharmacol.Exp.Ther. 2002; 300: 724-728" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Bergh JJ, Shao Y, Puente E, Duncan RL, Farach-Carson MC. Osteoblast Ca(2+) permeability and voltage-sensitive Ca(2+) channel expression is temporally regulated by 1,25-dihydroxyvitamin D(3). Am.J.Physiol Cell Physiol 2006; 290: C822-C831" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hayashi K, Wakino S, Homma K, Sugano N, Saruta T. Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation. J.Pharmacol.Sci. 2005; 99: 221-227 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16293936" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Martinez Martin FJ. [Calcium channel-blockers for managing metabolic syndrome-associated hypertension. Trials with manidipine]. Nefrologia. 2007; 27 Suppl 6: 26-35 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18225601" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Sabbatini M, Leonardi A, Testa R, Vitaioli L, Amenta F. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35: 775-779 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10720594" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609-611 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12411451" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Martinez Martin FJ. Manidipne (but not amlodipine), increases insulin sensitivity and rises plasma adiponectin cocentrations in hypertensive non-diabetic patients with metabolic syndrome and impaired fasting glucose. Diabetologia 2005; 48 Suppl 1: A374" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Fogari R, Derosa G, Zoppi A et al. Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Intern.Med. 2008; 47: 361-366 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18310964" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Nakami T, Martinez MFJ. Manidipine prevents hepatic C-reactive protein production and reactive oxygen species generation by down-regulation of the age receptor expression, dependent on PPAR-gamma activation. Journal of Hypertension 2007; 25: S119-S120" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Oshimura H, Nakami T, Javier MF. Manidipine has a marked non-haemodynamic nephroprotective action; Partly dependent on PPAR-gamma activation, and synergistic with angiotensin receptor blockade. Journal of Hypertension 2007; 25: S8" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Meldolesi J. Inhibition of adipogenesis: a new job for the ER Ca2+ pool. J.Cell Biol. 2008; 182: 11-13 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18606853" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Szabo E, Qiu Y, Baksh S, Michalak M, Opas M. Calreticulin inhibits commitment to adipocyte differentiation. J.Cell Biol. 2008; 182: 103-116 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18606846" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Simon A, Levenson J. Effects of calcium channel blockers on atherosclerosis: new insights. Acta Cardiol. 2002; 57: 249-255 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12222691" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Adams DJ, Barakeh J, Laskey R, Van Breemen C. Ion channels and regulation of intracellular calcium in vascular endothelial cells. FASEB J. 1989; 3: 2389-2400 <a href="http://www.ncbi.nlm.nih.gov/pubmed/2477294" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Berkels R, Breitenbach T, Bartels H et al. Different antioxidative potencies of dihydropyridine calcium channel modulators in various models. Vascul.Pharmacol. 2005; 42: 145-152 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15820440" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 25 => array:3 [ "identificador" => "bib26" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Toba H, Nakagawa Y, Miki S et al. Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine. Hypertens.Res. 2005; 28: 689-700 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16392774" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 26 => array:3 [ "identificador" => "bib27" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Toba H, Shimizu T, Miki S et al. Calcium [corrected] channel blockers reduce angiotensin II-induced superoxide generation and inhibit lectin-like oxidized low-density lipoprotein receptor-1 expression in endothelial cells. Hypertens.Res. 2006; 29: 105-116 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16755144" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 27 => array:3 [ "identificador" => "bib28" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Sun X, Zemel MB. Calcitriol and calcium regulate cytokine production and adipocyte-macrophage cross-talk. J.Nutr.Biochem. 2008; 19: 392-399 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17869082" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000002900000003/v0_201502091629/X2013251409004564/v0_201502091629/en/main.assets" "Apartado" => array:4 [ "identificador" => "35445" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Short Reviews" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000002900000003/v0_201502091629/X2013251409004564/v0_201502091629/en/P-E-S-A171-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409004564?idApp=UINPBA000064" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 6 | 8 | 14 |
2024 October | 52 | 320 | 372 |
2024 September | 47 | 48 | 95 |
2024 August | 63 | 68 | 131 |
2024 July | 70 | 28 | 98 |
2024 June | 63 | 34 | 97 |
2024 May | 72 | 25 | 97 |
2024 April | 59 | 27 | 86 |
2024 March | 40 | 27 | 67 |
2024 February | 51 | 41 | 92 |
2024 January | 37 | 104 | 141 |
2023 December | 36 | 31 | 67 |
2023 November | 39 | 60 | 99 |
2023 October | 48 | 39 | 87 |
2023 September | 43 | 45 | 88 |
2023 August | 36 | 30 | 66 |
2023 July | 57 | 41 | 98 |
2023 June | 86 | 32 | 118 |
2023 May | 68 | 38 | 106 |
2023 April | 60 | 20 | 80 |
2023 March | 85 | 26 | 111 |
2023 February | 44 | 22 | 66 |
2023 January | 42 | 22 | 64 |
2022 December | 55 | 25 | 80 |
2022 November | 46 | 25 | 71 |
2022 October | 60 | 39 | 99 |
2022 September | 49 | 30 | 79 |
2022 August | 52 | 47 | 99 |
2022 July | 46 | 45 | 91 |
2022 June | 45 | 21 | 66 |
2022 May | 35 | 33 | 68 |
2022 April | 57 | 49 | 106 |
2022 March | 44 | 41 | 85 |
2022 February | 55 | 38 | 93 |
2022 January | 42 | 27 | 69 |
2021 December | 31 | 35 | 66 |
2021 November | 56 | 59 | 115 |
2021 October | 48 | 53 | 101 |
2021 September | 63 | 28 | 91 |
2021 August | 66 | 40 | 106 |
2021 July | 61 | 40 | 101 |
2021 June | 42 | 18 | 60 |
2021 May | 60 | 29 | 89 |
2021 April | 120 | 30 | 150 |
2021 March | 80 | 13 | 93 |
2021 February | 85 | 20 | 105 |
2021 January | 74 | 15 | 89 |
2020 December | 34 | 4 | 38 |
2020 November | 33 | 19 | 52 |
2020 October | 16 | 5 | 21 |
2020 September | 24 | 9 | 33 |
2020 August | 36 | 11 | 47 |
2020 July | 47 | 9 | 56 |
2020 June | 45 | 7 | 52 |
2020 May | 42 | 11 | 53 |
2020 April | 37 | 7 | 44 |
2020 March | 43 | 14 | 57 |
2020 February | 32 | 11 | 43 |
2020 January | 57 | 20 | 77 |
2019 December | 52 | 15 | 67 |
2019 November | 65 | 16 | 81 |
2019 October | 61 | 10 | 71 |
2019 September | 40 | 6 | 46 |
2019 August | 29 | 10 | 39 |
2019 July | 27 | 22 | 49 |
2019 June | 15 | 6 | 21 |
2019 May | 24 | 1 | 25 |
2019 April | 49 | 20 | 69 |
2019 March | 15 | 14 | 29 |
2019 February | 24 | 8 | 32 |
2019 January | 26 | 18 | 44 |
2018 December | 59 | 24 | 83 |
2018 November | 55 | 11 | 66 |
2018 October | 58 | 8 | 66 |
2018 September | 51 | 7 | 58 |
2018 August | 26 | 18 | 44 |
2018 July | 30 | 5 | 35 |
2018 June | 28 | 9 | 37 |
2018 May | 24 | 13 | 37 |
2018 April | 20 | 7 | 27 |
2018 March | 30 | 8 | 38 |
2018 February | 27 | 6 | 33 |
2018 January | 30 | 8 | 38 |
2017 December | 35 | 7 | 42 |
2017 November | 28 | 9 | 37 |
2017 October | 32 | 12 | 44 |
2017 September | 27 | 10 | 37 |
2017 August | 33 | 15 | 48 |
2017 July | 22 | 8 | 30 |
2017 June | 47 | 17 | 64 |
2017 May | 31 | 10 | 41 |
2017 April | 28 | 10 | 38 |
2017 March | 14 | 20 | 34 |
2017 February | 22 | 15 | 37 |
2017 January | 22 | 10 | 32 |
2016 December | 63 | 6 | 69 |
2016 November | 81 | 14 | 95 |
2016 October | 68 | 17 | 85 |
2016 September | 113 | 17 | 130 |
2016 August | 189 | 10 | 199 |
2016 July | 142 | 11 | 153 |
2016 June | 120 | 0 | 120 |
2016 May | 135 | 0 | 135 |
2016 April | 89 | 0 | 89 |
2016 March | 70 | 0 | 70 |
2016 February | 91 | 0 | 91 |
2016 January | 84 | 0 | 84 |
2015 December | 98 | 0 | 98 |
2015 November | 63 | 0 | 63 |
2015 October | 59 | 0 | 59 |
2015 September | 69 | 0 | 69 |
2015 August | 60 | 0 | 60 |
2015 July | 58 | 0 | 58 |
2015 June | 24 | 0 | 24 |
2015 May | 55 | 0 | 55 |
2015 April | 6 | 0 | 6 |